KR100962334B1 - 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 - Google Patents
울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 Download PDFInfo
- Publication number
- KR100962334B1 KR100962334B1 KR1020090099238A KR20090099238A KR100962334B1 KR 100962334 B1 KR100962334 B1 KR 100962334B1 KR 1020090099238 A KR1020090099238 A KR 1020090099238A KR 20090099238 A KR20090099238 A KR 20090099238A KR 100962334 B1 KR100962334 B1 KR 100962334B1
- Authority
- KR
- South Korea
- Prior art keywords
- curcumin
- tamiflu
- virus
- swine
- swine flu
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 83
- 241000712461 unidentified influenza virus Species 0.000 title description 40
- 241000725681 Swine influenza virus Species 0.000 title description 24
- 230000002401 inhibitory effect Effects 0.000 title description 18
- 239000003443 antiviral agent Substances 0.000 title description 2
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims abstract description 88
- 229940061367 tamiflu Drugs 0.000 claims abstract description 87
- 201000010740 swine influenza Diseases 0.000 claims abstract description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 66
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 39
- 208000002979 Influenza in Birds Diseases 0.000 claims abstract description 38
- 206010064097 avian influenza Diseases 0.000 claims abstract description 38
- 241000271566 Aves Species 0.000 claims abstract description 25
- 239000008513 turmeric extract Substances 0.000 claims abstract description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010069767 H1N1 influenza Diseases 0.000 claims abstract description 19
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims abstract description 16
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims abstract description 16
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims abstract description 16
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims abstract description 16
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims abstract description 16
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 244000163122 Curcuma domestica Species 0.000 claims description 42
- 235000003373 curcuma longa Nutrition 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 25
- 229940109262 curcumin Drugs 0.000 claims description 24
- 235000012754 curcumin Nutrition 0.000 claims description 24
- 239000004148 curcumin Substances 0.000 claims description 24
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 235000020240 turmeric extract Nutrition 0.000 claims description 22
- 229940052016 turmeric extract Drugs 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000003674 animal food additive Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 108010006232 Neuraminidase Proteins 0.000 abstract description 78
- 102000005348 Neuraminidase Human genes 0.000 abstract description 77
- 239000000203 mixture Substances 0.000 abstract description 19
- 208000037797 influenza A Diseases 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 91
- 230000000694 effects Effects 0.000 description 45
- 239000000284 extract Substances 0.000 description 40
- 235000003392 Curcuma domestica Nutrition 0.000 description 34
- 235000013976 turmeric Nutrition 0.000 description 34
- 238000000034 method Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 13
- 235000013330 chicken meat Nutrition 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000469 ethanolic extract Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 6
- 239000002038 ethyl acetate fraction Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000036963 noncompetitive effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001555 benzenes Chemical group 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002034 butanolic fraction Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000037801 influenza A (H1N1) Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229930153442 Curcuminoid Natural products 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- FKWGCEDRLNNZOZ-GFCCVEGCSA-N Xanthorrhizol Chemical compound CC(C)=CCC[C@@H](C)C1=CC=C(C)C(O)=C1 FKWGCEDRLNNZOZ-GFCCVEGCSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 235000021438 curry Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000007986 glycine-NaOH buffer Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101150008604 CAN1 gene Proteins 0.000 description 1
- 101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
- 101100279438 Caenorhabditis elegans egg-3 gene Proteins 0.000 description 1
- 101100279440 Caenorhabditis elegans egg-4 gene Proteins 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 244000164418 Curcuma xanthorrhiza Species 0.000 description 1
- 235000003393 Curcuma xanthorrhiza Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 102220539924 Nurim_R292K_mutation Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 101150073877 egg-1 gene Proteins 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- -1 histidine amino acid Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102200094936 rs121913561 Human genes 0.000 description 1
- 102220149223 rs886059906 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- FKWGCEDRLNNZOZ-UHFFFAOYSA-N xanthorrhizol Natural products CC(C)=CCCC(C)C1=CC=C(C)C(O)=C1 FKWGCEDRLNNZOZ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
조건 |
추출량 |
돼지 인플루엔자 바이러스 기원 뉴라미니데이즈에 대한 저해활성(20μg/㎖) |
30% 에탄올 |
7.3g |
18.1% |
50% 에탄올 |
6.6g |
39.1% |
70% 에탄올 |
6.5g |
40.1% |
90% 에탄올 |
5.2g |
32.0% |
에탄올 |
4.1g |
40.4% |
메탄올 |
6.6g |
38.2% |
아세톤 |
5.0g |
34.2% |
에틸아세테이트 |
5.5g |
30.3% |
클로로포름 |
6.1g |
27.5% |
증류수 |
8.1g |
9.72% |
조건 |
신종플루(novel influenza) 바이러스의 뉴라미니데이즈에 대한 IC50 | 타미플루 내성 바이러스의 신종플루 뉴라미니데이즈에 대한 IC50 |
화합물 1 (㎍/㎖) |
3.46±0.06 |
6.50±0.53 |
화합물 2 (㎍/㎖) |
4.37±0.57 |
11.29±0.55 |
화합물 3 (㎍/㎖) |
6.95±1.00 |
13.74±1.64 |
타미플루 (nM) |
1 |
> 20 |
curcumin, M.W. 368 ; demethoxycurcumin, M.W. 338 ; bisdemethoxycurcumin, M.W. 308 |
조건 |
조류 인플루엔자 바이러스 (H9N2)의 뉴라미니데이즈에 대한 저해활성(20μg/㎖) | 돼지 인플루엔자 바이러스 (H1N1)의 뉴라미니데이즈에 대한 저해활성(20μg/㎖) |
A 분획 (에탄올 추출물) |
27.8% |
35.0% |
B 분획 (헥산 추출물) |
0% |
5.2% |
C 분획 (에틸아세테이트 추출물) |
58.3% |
55.8% |
D 분획 (부탄올 추출물) |
49.1% |
51.7% |
조건 | 조류 인플루엔자 바이러스 (H9N2)의 뉴라미니데이즈에 대한 IC50 측정값 | 돼지 인플루엔자 바이러스 (H1N1)의 뉴라미니데이즈에 대한 IC50 측정값 |
화합물 1 (μg/㎖) |
6.18±0.27 |
8.20±0.99 |
화합물 2 (μg/㎖) |
7.73±0.20 |
10.26±0.54 |
화합물 3 (μg/㎖) |
9.90±0.86 |
13.10±0.53 |
타미플루 (nM) |
12.05±1.00 |
96.89±7.41 |
뉴라미니데이즈 종류 |
커큐민 10μM과 병행한 타미플루 농도 |
|||||||||
0.24 nM |
0.48 nM |
0.98 nM |
1.9 nM |
3.9 nM |
7.8 nM |
15.6 nM |
31.3 nM | 62.5 nM | 125 nM | |
조류 인플루엔자 바이러스(H9N2)의 뉴라미니데이즈 활성 저해율(%) | 37.1% |
48.5% |
50.0% |
51.9% |
53.0% |
58.9% |
67.6% |
77.9% |
93.3% |
98.7% |
돼지 인플루엔자 바아러스(H1N1)의 뉴라미니데이즈활성 저해율(%) | 33.2% |
34.8% |
36.5% |
42.2% |
47.2% |
52.1% |
53.1% |
61.1% |
75.3% |
84.0% |
조건 |
조류 인플루엔자 바이러스(H9N2)의 적혈구 응집저해작용 | 돼지 인플루엔자 바이러스(H1N1)의 적혈구 응집저해작용 |
A 분획 (에탄올 추출물) |
없음(-) |
없음(-) |
B 분획 (헥산 추출물) |
없음(-) |
없음(-) |
C 분획 (에틸아세테이트 추출물) |
있음(+) |
있음(+) |
D 분획 (부탄올 추출물) |
없음(-) |
없음(-) |
화합물 1 |
있음(+) |
있음(+) |
화합물 2 |
있음(+) |
있음(+) |
화합물 3 |
있음(+) |
있음(+) |
타미플루 |
있음(+) |
있음(+) |
조건 |
수정란 1 |
수정란 2 |
수정란 3 |
수정란 4 |
1. 메탄올 30% 추출물 |
1:128 |
1:128 |
1:256 |
1:128 |
2. 메탄올 70% 추출물 |
-* |
- |
1:128 |
1:128 |
3. 메탄올 100% 추출물 |
1:128 |
- |
1:256 |
- |
4. 아세톤 추출물 |
1:64 |
1:256 |
1:128 |
1:128 |
5. 에탄올 30% 추출물 |
1:256 |
1:256 |
1:256 |
1:256 |
6. 에탄올 70% 추출물 |
1:128 |
1:128 |
1:256 |
1:256 |
7. 에탄올 100% 추출물 (실시예 1의 A 분획) |
1:32 |
1:256 |
1:128 |
1:128 |
8. n-헥산 분획 (실시예 1의 B 분획) |
1:128 |
1:128 |
1:128 |
1:256 |
9. 에틸아세테이스 분획 (실시예 1의 C 분획) |
- |
1:256 |
1:128 |
- |
10. 부탄올 분획 (실시예 1의 D 분획) |
1:128 |
1:256 |
1:256 |
1:128 |
11. 화합물 1 |
- |
- |
- |
- |
12. 화합물 2 |
- |
- |
- |
- |
13. 화합물 3 |
- |
- |
- |
- |
14. 타미플루 (양성대조군) |
1:256 |
1:256 |
1:256 |
1:256 |
15. 음성대조군 |
1:256 |
1:256 |
1:256 |
1:256 |
상기 조건 1 내지 7은 울금 1㎏을 사용 용매 3ℓ을 사용하여 4시간 동안 3회에 걸쳐 환류 냉각기를 이용하여 얻은 다음 용매를 제거하여 얻은 울금 추출물임 -* <1:2의 음성을 의미함 1:32, 1:64, 1:128, 1:256; 배양액의 희석배수(HA units) |
Specificity and size |
Primer/Probe |
Sequence* |
Matrix gene, 100 base pairs |
M-F |
5'-AGA TGA GTC TTC TAA CCG AGG TCG-3' |
M-R |
5'-TGC AAA AAC ATC TTC AAG TCT CTG-3' |
|
M-Probe |
FAM-TCA GGC CCC CTC AAA GCC GA-TAMRA |
|
* Realtime PCR target gene : Influenza virus type A의 Matrix gene (Reference : J. Vet. Diagn. Invest 16:367-373(2004) |
조건 |
각 개체의 ID | 정량값(Ct) | |
4 일 | 6 일 | ||
커큐민(20㎎/㎏/day로 경구 투여한 군) |
C-1 |
25.2 |
30.21 |
C-2 |
22.5 |
28.39 |
|
C-3 |
23.7 |
28.86 |
|
C-4 |
29.6 |
31.29 |
|
C-5 |
25.7 |
28.80 |
|
평균 |
25.3 ± 2.7 |
29.5 ± 1.2 |
|
타미플루(10㎎/㎏/day로경구 투여한 군) |
T-1 |
Undetermined |
Undetermined |
T-2 |
Undetermined |
29.0 |
|
T-3 |
32.8 |
36.5 |
|
T-4 |
Undetermined |
30.7 |
|
T-5 |
Undetermined |
31.2 |
|
평균 |
Undetermined |
31.9 ± 3.3 |
Claims (12)
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 것을 특징으로 하는 울금추출물을 활성성분으로 포함하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 약학조성물.
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 것을 특징으로 하는 울금추출물을 활성성분으로 포함하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 개선용 건강기능식품.
- 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민 중 적어도 하나 이상을 유효성분으로 함유하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 약학조성물.
- 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민 중 적어도 하나 이상을 유효성분으로 함유하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 개선용 건강기능식품.
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 울금추출물과 타미플루를 유효성분으로 포함하는 조류 및 돼지 인플루엔자와 신종플루 및 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 약학조성물.
- 삭제
- 삭제
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 울금추출물과 타미플루를 유효성분으로 포함하는 조류 및 돼지 인플루엔자와 신종플루 및 타미플루 내성 신종플루 관련 질환의 예방 또는 개선용 건강기능식품.
- 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민 중 적어도 하나 이상의 화합물과 타미플루를 유효성분으로 함유하는 것을 특징으로 하는 조류 및 돼지 인플루엔자와 신종플루 및 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 약학조성물.
- 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민 중 적어도 하나 이상의 화합물과 타미플루를 유효성분으로 함유하는 것을 특징으로 하는 조류 및 돼지 인플루엔자와 신종플루 및 타미플루 내성 신종플루 관련 질환의 예방 또는 개선용 건강기능식품
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 것을 특징으로 하는 울금추출물을 활성성분으로 포함하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 사료첨가제.
- 울금(Curcuma longa)을 에탄올, 메탄올, 아세톤, 에틸아세테이트 또는 클로로포름 중에서 선택된 1종 이상의 추출용매로 추출하여 비스데메톡시커큐민, 데메톡시커큐민(demethoxycurcumin) 또는 커큐민의 화합물 중 적어도 하나이상 함유하는 것을 특징으로 하는 울금추출물을 활성성분으로 포함하는 것을 특징으로 하는 타미플루 내성 신종플루 관련 질환의 예방 또는 치료용 천연소독제.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090099238A KR100962334B1 (ko) | 2009-10-19 | 2009-10-19 | 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 |
PCT/KR2010/007154 WO2011049348A2 (ko) | 2009-10-19 | 2010-10-19 | 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090099238A KR100962334B1 (ko) | 2009-10-19 | 2009-10-19 | 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100962334B1 true KR100962334B1 (ko) | 2010-06-10 |
Family
ID=42369792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090099238A KR100962334B1 (ko) | 2009-10-19 | 2009-10-19 | 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100962334B1 (ko) |
WO (1) | WO2011049348A2 (ko) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101273276B1 (ko) * | 2010-12-30 | 2013-06-12 | 대한민국 | 커큐민을 첨가한 가축용 사료의 제조방법 및 상기 방법으로 제조된 가축용 사료 |
US20140248382A1 (en) * | 2011-06-13 | 2014-09-04 | Korea Research Institute Of Bioscience And Biotechnology | Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection |
WO2015111904A1 (ko) * | 2014-01-21 | 2015-07-30 | 한국생명공학연구원 | 커큐미노이드계 화합물, 및 감초 추출물 또는 이의 분획물을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20160108689A (ko) | 2015-03-05 | 2016-09-20 | 충남대학교산학협력단 | 강황 분말을 함유하는 발효유 및 이를 포함하는 면역증강용 조성물 |
KR101853076B1 (ko) * | 2011-11-08 | 2018-04-27 | 한국생명공학연구원 | 커큐민을 포함하는 살바이러스 또는 살균용 조성물 |
JP2018086003A (ja) * | 2018-01-29 | 2018-06-07 | ハウスウェルネスフーズ株式会社 | ビサクロン抽出方法 |
KR20210091949A (ko) | 2020-01-15 | 2021-07-23 | 한국수목원관리원 | 머위 추출물을 유효성분으로 함유하는 패혈증 예방, 개선 또는 치료용 조성물 |
KR20220076565A (ko) | 2020-11-30 | 2022-06-08 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20220102695A (ko) | 2021-01-13 | 2022-07-21 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115770236A (zh) * | 2021-09-08 | 2023-03-10 | 四川省中医药转化医学中心 | 姜黄在制备抗呼吸道病毒的药物中的用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020084336A (ko) * | 2001-04-27 | 2002-11-07 | 주식회사 싸이제닉 | 커큐민 또는 이의 유도체를 포함하는 치매 예방 및 치료용조성물 |
CA2495447A1 (en) * | 2002-08-06 | 2004-02-12 | The Quigley Corporation | Anti-microbial compositions and methods of using same |
JP4012894B2 (ja) * | 2003-09-17 | 2007-11-21 | レキオファーマ株式会社 | ウコン含有組成物 |
KR100802904B1 (ko) * | 2006-12-14 | 2008-02-13 | 주식회사오뚜기 | 강황 함유 음료의 제조방법 |
-
2009
- 2009-10-19 KR KR1020090099238A patent/KR100962334B1/ko active IP Right Grant
-
2010
- 2010-10-19 WO PCT/KR2010/007154 patent/WO2011049348A2/ko active Application Filing
Non-Patent Citations (2)
Title |
---|
Food Chem., Vol.119, No.4, pp1346~1351(2009.09.10.) 1부.* |
Swine Flu Cytokine Storm Cures (2009.04.28.)* |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101273276B1 (ko) * | 2010-12-30 | 2013-06-12 | 대한민국 | 커큐민을 첨가한 가축용 사료의 제조방법 및 상기 방법으로 제조된 가축용 사료 |
US20140248382A1 (en) * | 2011-06-13 | 2014-09-04 | Korea Research Institute Of Bioscience And Biotechnology | Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection |
US10136663B2 (en) * | 2011-06-13 | 2018-11-27 | Korea Research Institute Of Bioscience And Biotechnology | Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection |
KR101853076B1 (ko) * | 2011-11-08 | 2018-04-27 | 한국생명공학연구원 | 커큐민을 포함하는 살바이러스 또는 살균용 조성물 |
WO2015111904A1 (ko) * | 2014-01-21 | 2015-07-30 | 한국생명공학연구원 | 커큐미노이드계 화합물, 및 감초 추출물 또는 이의 분획물을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20160108689A (ko) | 2015-03-05 | 2016-09-20 | 충남대학교산학협력단 | 강황 분말을 함유하는 발효유 및 이를 포함하는 면역증강용 조성물 |
JP2018086003A (ja) * | 2018-01-29 | 2018-06-07 | ハウスウェルネスフーズ株式会社 | ビサクロン抽出方法 |
KR20210091949A (ko) | 2020-01-15 | 2021-07-23 | 한국수목원관리원 | 머위 추출물을 유효성분으로 함유하는 패혈증 예방, 개선 또는 치료용 조성물 |
KR20220076565A (ko) | 2020-11-30 | 2022-06-08 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20220102695A (ko) | 2021-01-13 | 2022-07-21 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR102578233B1 (ko) | 2021-01-13 | 2023-09-15 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2011049348A3 (ko) | 2011-09-22 |
WO2011049348A2 (ko) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100962334B1 (ko) | 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 | |
US8545903B2 (en) | Composition for the prevention and treatment of influenza virus infection and composition for suppressing neuraminidase activity comprising turmeric extract | |
KR101021830B1 (ko) | 크레이스토카릭스 오페르쿠라투스로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 | |
KR100950445B1 (ko) | 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 | |
KR101782532B1 (ko) | 백지 추출물 또는 이로부터 분리된 퓨라노쿠마린을 함유하는 조류 인플루엔자, 돼지 인플루엔자 또는 코로나 바이러스의 예방 또는 치료용 조성물 | |
KR101317318B1 (ko) | 신종인플루엔자, 조류인플루엔자, 일반 및 독감감기, sars 바이러스 억제 효능을 갖는 오배자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 약학 조성물 | |
KR101334143B1 (ko) | 폴리갈라 카렌시움 추출물 및 이로부터 분리된 잔톤계 화합물을 함유하는 감기, 조류 인플루엔자, 돼지 인플루엔자 또는 신종플루의 예방 또는 치료용 조성물 | |
KR101976528B1 (ko) | 미역 추출물을 함유하는 코로나 바이러스의 예방 또는 치료용 조성물 | |
KR20150055683A (ko) | 진세노사이드를 함유하는 감기, 조류 인플루엔자 또는 돼지 인플루엔자의 예방 또는 치료용 조성물 | |
KR101189823B1 (ko) | 폴리페놀성 화합물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 | |
KR101427096B1 (ko) | 관중 추출물 또는 이로부터 분리된 플로로글루시놀 유도체를 함유하는 코로나 바이러스 관련 질환의 예방 또는 치료용 조성물 | |
KR101966124B1 (ko) | 감태 추출물 또는 이로부터 분리한 플로로탄닌계 화합물을 유효성분으로 포함하는 인플루엔자의 예방 또는 치료용 조성물 | |
US10136663B2 (en) | Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection | |
US20120046353A1 (en) | Cleistocalyx operculatus-derived compounds having inhibitory activities against avian and swine influenza viruses or novel influenza virus | |
KR20210133861A (ko) | 소나무 송지 추출물 또는 이로부터 분리한 다이테르페노이드계 화합물을 유효성분으로 포함하는 돼지 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 | |
KR20150095605A (ko) | 진세노사이드를 함유하는 감기, 조류 인플루엔자 또는 돼지 인플루엔자의 예방 또는 치료용 조성물 | |
KR101115063B1 (ko) | 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 | |
KR101636606B1 (ko) | 장수진흙버섯 자실체로부터 분리된 폴리페놀성분을 포함하는 인플루엔자 바이러스 감염 예방 및 치료용 조성물 | |
KR20070114947A (ko) | 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방 및 치료제 | |
KR102070040B1 (ko) | 톳 추출물을 유효성분으로 포함하는 인플루엔자 예방 또는 치료용 조성물 | |
KR101189822B1 (ko) | 쿠마린계 화합물을 포함하는 뉴라미니데이즈 활성의 억제용 조성물 및 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물 | |
KR20230146695A (ko) | 인플루엔자 바이러스 억제용 조성물 | |
KR100853442B1 (ko) | 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방용 건강식품 | |
KR101376206B1 (ko) | 수수 천연색소 추출물 또는 이로부터 분리한 폴리페놀 화합물을 포함하는 항박테리아 또는 항바이러스 활성을 가지는 조성물 | |
KR20230043279A (ko) | 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130425 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140516 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150519 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170526 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190521 Year of fee payment: 10 |